8-K: TriSalus Life Sciences Reports Strong Q3 Revenue Growth and Positive 2025 Outlook

TriSalus Life Sciences announced a 42% year-over-year increase in Q3 revenue and provided optimistic guidance for 2025, including expectations for positive EBITDA and cash flow.

Summary

• TriSalus Life Sciences reported a 42% increase in revenue for the third quarter of 2024, reaching $7.3 million, and a 66% increase for the first nine months of the year, totaling $21.2 million.
• The company launched the TriNav LV Infusion System and TriGuide Guiding Catheter, expanding its reach in the $375 million liver embolization market.
• TriSalus initiated the PROTECT registry trial for multinodular goiters, targeting a $400 million thyroid embolization market.
• Positive Phase 1 data from the PERIO-01 trial for uveal melanoma with liver metastases was presented, and the company is seeking a strategic partner for further development.
• The company anticipates data from its Phase 1 study in locally advanced pancreatic cancer by mid-2025.
• TriSalus is projecting over 50% annual sales growth for 2025, along with a greater than 20% reduction in operating expenses.
• The company expects to achieve positive full-year EBITDA and positive cash flow in the second half of 2025.
• Gross margins were 86% for both the three and nine months ended September 30, 2024.
• Operating losses decreased to $8.7 million for the quarter and $28.6 million for the nine months ended September 30, 2024.
• Net losses were $2.4 million for the quarter and $19.9 million for the nine months ended September 30, 2024.
• As of September 30, 2024, cash and cash equivalents totaled $11.3 million, with an additional $25 million available through a debt facility.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, optimistic 2025 guidance, and progress in clinical trials. However, the company is still operating at a loss and is reliant on external funding, which tempers the overall sentiment.

Positives

• The company experienced significant revenue growth in Q3 2024, with a 42% increase year-over-year.
• The launch of the TriNav LV system and TriGuide Guiding Catheter expands the company's addressable market.
• The initiation of the PROTECT registry trial opens up a new market opportunity in thyroid embolization.
• Positive Phase 1 data from the PERIO-01 trial suggests potential for the company's immunotherapy candidate.
• The company is projecting strong sales growth and improved profitability for 2025.
• Operating losses have decreased compared to the same periods in 2023.
• The company has sufficient cash runway to operate through 2025.

Negatives

• The company reported net losses of $2.4 million for the quarter and $19.9 million for the nine months ended September 30, 2024.
• The company is still reliant on external funding to maintain operations.
• The company is seeking a strategic partner to advance the PERIO-01 trial, indicating a need for external resources.

Risks

• The company's future financial performance is subject to risks associated with clinical development and regulatory approval.
• The company may not be successful in identifying a strategic partner to advance the PERIO-01 trial.
• The company may not achieve its projected financial results for 2025.
• The company is subject to risks associated with its credit facility, including the ability to remain in compliance.
• The company may need to raise additional capital through the issuance and sale of its equity securities.
• The company faces competition and market risks that could impact its performance.

Future Outlook

TriSalus anticipates over 50% sales growth in 2025, a greater than 20% reduction in operating expenses, positive full-year EBITDA, and positive cash flow in the second half of 2025.

Management Comments

• We enter the final quarter of 2024 with great momentum, both commercially and clinically, and we are positioned well for an even greater 2025, stated Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences.
• Commercially, we enjoyed a strong third quarter highlighted by 42% revenue growth.
• With the successful completion of our Phase 1 dose escalation study enrollment in UM-LM, we are actively pursuing a strategic partnership for nelitolimod.
• Finally, we are initiating 2025 guidance that calls for greater than 50% revenue growth, a greater than 20% reduction in operating expenses, positive full-year EBITDA, and positive cash flow in the second half of the year, concluded Ms. Szela.

Industry Context

This announcement highlights TriSalus's progress in the oncology space, particularly in the areas of drug delivery and immunotherapy. The company's focus on liver and pancreatic tumors aligns with the growing need for innovative treatments in these areas. The expansion into the thyroid embolization market also demonstrates the company's ability to leverage its technology in new therapeutic areas.

Comparison to Industry Standards

• TriSalus's 42% revenue growth in Q3 is strong compared to many early-stage biotech companies, but it is important to compare this to other companies in the drug delivery and oncology space.
• Companies like Sirtex Medical (acquired by CDH Investments) and Boston Scientific, which have established positions in interventional oncology, serve as benchmarks for market penetration and revenue growth.
• The projected 50% sales growth for 2025 is ambitious and will need to be closely monitored against actual performance.
• The expectation of positive EBITDA and cash flow in 2025 is a significant milestone, as many biotech companies struggle to achieve profitability in the early stages.
• The company's focus on expanding its addressable market through new product launches and clinical trials is a common strategy in the medical device and biotech industries.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and positive 2025 outlook.
• Employees may be encouraged by the company's progress and future prospects.
• Customers (healthcare providers) will benefit from the expanded product portfolio and clinical data.
• Suppliers may see increased demand for their products and services.
• Creditors will be reassured by the company's improved financial performance and cash runway.

Next Steps

• TriSalus will continue to enroll patients in the PROTECT registry trial.
• The company will seek a strategic partner to advance the PERIO-01 trial.
• TriSalus will release data from the Phase 1 study in locally advanced pancreatic cancer in mid-2025.
• The company will open additional DELIVER studies in the first half of 2025.
• TriSalus will focus on achieving its 2025 financial guidance.

Key Dates

Keywords

TriSalus, Oncology, Drug Delivery, Immunotherapy, TriNav System, Liver Cancer, Pancreatic Cancer, Embolization, EBITDA, Financial Results, Clinical Trials, Nelitolimod